Specialized pathology review in patients with ovarian cancer results from a prospective study

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1376-1382

  Kommoss, Stefan ^a   Pfisterer, Jacobus ^b,c   Reuss, Alexander ^d   Diebold, Joachim ^e   Hauptmann, Steffen ^f   Schmidt, Christine ^e   Du Bois, Andreas ^b,g   Schmidt, Dietmar ^h   Kommoss, Friedrich ^h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b AGO Study Group   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^e Institute of Pathology   (Germany)

^f DR HORST SCHMIDT KLINIKEN   (Germany)

^g Gynecologic Oncology Center Kiel   (Germany)

^h KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Borderline tumor; Case review; Clinical trial; Metastasis; Ovarian carcinoma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADENOCARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL RESEARCH; DIAGNOSTIC ERROR; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MESOTHELIOMA; OVARY CARCINOMA; OVARY METASTASIS; PATHOLOGIST; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR INVASION;

CARCINOMA; DIAGNOSTIC ERRORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY; PEER REVIEW, HEALTH CARE; PROSPECTIVE STUDIES;

EID: 84888236851     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a01813     Document Type: Article

References (32)

1. Leitao MM Jr, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004;28:147-159.
2. Santoso JT, Coleman RL, Voet RL, et al. Pathology slide review in gynecologic oncology. Obstet Gynecol. 1998;91:730-734.
3. Sengupta PS, Shanks JH, Buckley CH, et al. Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer. 2000;82:760-762.
4. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Howlader N, Noone AM, Krapcho M, et al., eds. Bethesda, MD: National Cancer Institute; 2012.
5. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006; 100:185-191.
6. Tinelli FG, Tinelli R, La Grotta F, et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand. 2007;86:81-87.
7. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365: 2484-2496.
8. Tavassoli FA DP. Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003.
9. Soslow R. Common diagnostic discrepancies. In: Soslow RA, Tornos C, eds. Diagnostic Pathology of Ovarian Tumors. New York, NY: Springer; 2011:11-14.
10. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791-1799.
11. Gobel U, Calaminus G, Schneider DT, et al. The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klin Padiatr. 2006;218:309-314.
12. Cadron I, Leunen K, Van Gorp T, et al. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25: 2928-2937.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
14. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19:1421-1427.
15. Morrow GR, Andrews PL, Hickok JT, et al. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10:389-398.
16. Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10:19-28.
17. Tannock IF, Ahles TA, Ganz PA, et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22:2233-2239.
18. Gordon LG, Scuffham PA, Beesley VL, et al. Medical costs and outcomes for Australian women with ovarian cancer. Int J Gynecol Cancer. 2010;20:757-765.
19. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
20. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
21. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33.
22. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerVshifting the paradigm. Hum Pathol. 2011;42:918-931.
23. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
24. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
25. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
26. Gershenson DPR. GOG-0241: Comparing First-line Therapies for Mucinous Ovarian or Fallopian Tube Cancer. 2011. Available at: http://www.cancer.gov/ clinicaltrials/featured/trials/GOG-0241.
27. Takano M, Kikuchi Y, Yaegashi N, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep. 2006;16:1301-1306.
28. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010;20:240-247.
29. Takakura S, Saito M, Ueda K, et al. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma. Int Surg. 2007;92:202-208.
30. Du Bois A, Rochon J, Lamparter C, et al. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183-191.
31. Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol. 2005;16:1801-1805.
32. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a trans-Canadian study. Am J Surg Pathol. 2010;34:984-993.